GLP-1 Use Is Rapidly Expanding Beyond Diabetes Care

GLP-1 receptor agonists were originally developed to improve blood sugar control in people with type 2 diabetes. Their ability to reduce hunger and body weight eventually led researchers to study them specifically as obesity treatments.

That transition has dramatically changed who uses the medications. A 2025 KFF poll found that 12% of U.S. adults reported currently taking a GLP-1 drug for diabetes, weight loss, heart disease, or another condition. Eighteen percent said they had used one at some point. In an earlier 2024 poll, 6% reported current use, suggesting that uptake had grown substantially in a relatively short period.

Research examining new prescriptions has also detected an increasing share of GLP-1 users without diabetes. This shift reflects several forces working at once: FDA approvals for chronic weight management, strong clinical trial results, greater recognition of obesity as a disease, widespread media coverage, and growing access through obesity clinics and telehealth services.

Diabetes treatment remains a major part of the story

The expansion into obesity care does not mean GLP-1 drugs have left diabetes behind. CDC data show that approximately 26.5% of U.S. adults with diagnosed diabetes used an injectable GLP-1 medication in 2024. That represented an estimated 6.9 million adults.

What has changed is that a diabetes diagnosis is no longer required for every medically appropriate use. Certain GLP-1-based products are specifically approved for people with obesity or qualifying overweight, whether or not they have diabetes.

What Are GLP-1 Drugs, and How Do They Support Weight Loss?

GLP-1 stands for glucagon-like peptide-1, a hormone released by the intestines after eating. It helps regulate blood sugar, signals fullness to the brain, and influences how quickly food moves through the stomach.

GLP-1 receptor agonists imitate some of these natural signals. Depending on the medication and the individual, treatment may:

• Reduce hunger between meals
• Increase fullness after smaller portions
• Decrease cravings or persistent thoughts about food
• Slow stomach emptying
• Improve the body’s insulin response when glucose is elevated

Tirzepatide works somewhat differently because it activates both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors. It is commonly described as a dual GIP/GLP-1 receptor agonist.

These medicines do not literally melt fat. Instead, they alter biological signals involved in appetite, food intake, and metabolism. For some patients, that feels like finally turning down a radio that has been loudly broadcasting “What are we eating next?” all day.

Which GLP-1 Drugs Are Used for Weight Management?

Several brand names are frequently mentioned together, but their FDA-approved uses are not identical.

Semaglutide

Semaglutide is sold under different brands. Wegovy is approved for long-term weight management in qualifying adults and certain adolescents. Ozempic is approved primarily for type 2 diabetes and related risk reduction. Although the products share an active ingredient, their labeling, doses, delivery systems, and approved uses differ.

Tirzepatide

Zepbound is the tirzepatide product approved for chronic weight management. Mounjaro is approved for type 2 diabetes. Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity, used together with reduced-calorie eating and increased physical activity.

Liraglutide

Saxenda, an earlier GLP-1 medication, is approved for chronic weight management and is taken daily rather than weekly. Newer weekly medications have attracted more attention because they generally produce greater average weight loss and require less frequent dosing.

Approved use versus off-label prescribing

A clinician may legally prescribe an approved medication for an off-label purpose when medically appropriate. However, using a diabetes-labeled product for weight management is not the same as using the corresponding obesity-labeled product according to its approved instructions. Insurance coverage may also depend heavily on the diagnosis, brand, and plan rules.

Who May Qualify for Prescription Weight-Loss Medication?

For adults, FDA-approved chronic weight-management drugs are generally intended for people with:

• A body mass index of 30 or higher, which is categorized as obesity; or
• A BMI of 27 or higher plus at least one weight-related condition, such as high blood pressure, abnormal cholesterol, cardiovascular disease, or obstructive sleep apnea.

BMI is a screening tool, not a complete medical biography. A thoughtful evaluation may also consider waist measurement, weight history, previous treatment attempts, medications, eating patterns, sleep, mobility, laboratory results, pregnancy plans, mental health, and the presence of obesity-related complications.

Someone hoping to lose five pounds before a beach weekend is not automatically an appropriate candidate. These medications are designed to treat chronic medical risk, not panic caused by an aggressively lit fitting-room mirror.

How Much Weight Can People Without Diabetes Lose?

Results vary, but clinical trials have demonstrated weight loss that was once unusual for nonsurgical treatment.

In the STEP 1 trial, adults with overweight or obesity who did not have diabetes received weekly semaglutide or placebo in addition to lifestyle counseling. After 68 weeks, the semaglutide group lost about 14.9% of starting body weight on average, compared with approximately 2.4% in the placebo group. About one-third of participants taking semaglutide lost at least 20%.

A 2025 head-to-head trial compared tirzepatide and semaglutide in adults with obesity who did not have diabetes. At 72 weeks, average weight reduction was approximately 20.2% with tirzepatide and 13.7% with semaglutide.

Those percentages are averages, not personal guarantees. One patient may lose considerably more, another may lose less, and some may stop because of side effects, cost, availability, or limited response. Trial participants also received structured support that may be more extensive than a hurried real-world appointment followed by a cheerful instruction to “eat better.”

Benefits May Extend Beyond the Number on the Scale

Weight reduction can improve blood pressure, mobility, blood sugar, triglycerides, sleep, joint discomfort, and quality of life. Certain benefits are also supported by dedicated clinical trials rather than assumed from weight loss alone.

Wegovy is approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and either overweight or obesity. In the major cardiovascular outcomes trial supporting that indication, serious cardiovascular events occurred in 6.5% of semaglutide recipients and 8% of placebo recipients.

Zepbound’s approval for obstructive sleep apnea was based on studies of adults with obesity who did not have type 2 diabetes. Participants receiving tirzepatide experienced meaningful reductions in nighttime breathing disturbances along with weight loss.

These developments reinforce an important point: treating obesity is not merely about changing appearance. The goal may be to reduce disease burden, improve daily function, and protect long-term health.

Common GLP-1 Side Effects

Because GLP-1-based drugs affect digestion, gastrointestinal symptoms are the most common complaints. They may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain or bloating
• Indigestion, reflux, or frequent burping

Symptoms often appear during dose escalation. Gradually increasing the dose gives the body time to adjust, which is why jumping ahead on the schedule is a terrible place to express one’s enthusiasm.

Eating large, fatty meals can worsen symptoms for some people. Smaller portions, slower eating, adequate fluids, and individualized dietary advice may help. Persistent vomiting or diarrhea can cause dehydration and may contribute to kidney injury, so severe symptoms should not be treated as an endurance contest.

Serious risks and important warnings

Depending on the specific product, warnings may include pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury related to dehydration, serious allergic reactions, and pulmonary aspiration during anesthesia or deep sedation.

Semaglutide and tirzepatide weight-management products carry boxed warnings concerning thyroid C-cell tumors observed in rodents. It is unknown whether they cause these tumors in humans. They should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Patients should tell surgical and anesthesia teams that they use a GLP-1 medication because delayed stomach emptying may affect procedural planning. Pregnancy and pregnancy planning also require a conversation with the prescribing clinician. Weight-loss medications are generally not used during pregnancy, and product-specific stopping instructions may apply before conception.

After reviewing clinical trials and large health databases, the FDA reported in 2026 that it found no increased risk of suicidal thoughts or behavior from GLP-1 receptor agonists and requested removal of that warning from affected weight-management labels. Any new or worsening mental health symptoms still deserve prompt medical attention, regardless of their suspected cause.

Why Cost, Coverage, and Discontinuation Matter

Starting a GLP-1 drug is only part of the treatment story. Remaining on it can be much harder.

In the 2025 KFF survey, 56% of people who had used a GLP-1 medication said it was difficult to afford. Fourteen percent said they stopped because of cost, while 13% cited side effects.

A large U.S. cohort study found that 64.8% of patients without type 2 diabetes discontinued a GLP-1 medication within one year, compared with 46.5% of patients who had diabetes. The difference may reflect insurance coverage, out-of-pocket expense, availability, expectations, and the fact that coverage for obesity treatment has historically been inconsistent.

Stopping is not a personal failure. It may mean the treatment was unaffordable, poorly tolerated, unavailable, or simply not the best medical fit. Still, patients should plan discontinuation with a clinician rather than stretching doses, buying questionable products, or switching brands through a group chat.

What Happens When GLP-1 Treatment Stops?

Obesity is a chronic, biologically regulated disease. When medication is withdrawn, appetite signals may return and weight regain is common. This resembles what happens when blood pressure rises after stopping an effective antihypertensive drug; the return of the condition does not prove that treatment was fraudulent.

Long-term plans may include continued medication, a different dose, a different drug, intensified behavioral support, obesity surgery, or another individualized strategy. The best plan is one that can be sustained medically, financially, and practically.

Maintaining muscle is especially important during weight loss. Adequate protein, resistance exercise, sleep, and appropriate calorie intake can help preserve lean tissue. The goal should be better health and function, not winning a competition to see who can eat the fewest spoonfuls of yogurt.

Why Unapproved and Compounded GLP-1 Products Require Caution

Compounded medications can serve legitimate medical needs in certain circumstances, but compounded products are not FDA-approved. The FDA does not review them for safety, effectiveness, or manufacturing quality before they reach patients in the same way it reviews approved drugs.

The agency has reported dosing mistakes involving compounded injectable semaglutide, including errors that required hospitalization. Concentrations can vary, and instructions involving milliliters, milligrams, or syringe units can be confusing. The FDA has also warned about fraudulent products, false pharmacy information, semaglutide salt forms, and marketing that makes compounded drugs appear identical to approved brands.

Consumers should be cautious of products sold without a valid prescription, vague “research” peptides, social-media sellers, and websites that treat medical screening as an annoying obstacle between the customer and the checkout button.

Questions to Ask Before Starting a GLP-1 Drug for Weight Loss

• Is this product FDA-approved for my diagnosis?
• What health improvements are we targeting besides weight?
• How will the dose be increased, and what happens if side effects occur?
• Could the medication interact with my current prescriptions?
• What is my realistic monthly cost after insurance?
• How will we monitor nutrition, muscle strength, and laboratory results?
• What is the plan if I cannot continue treatment?
• Do my pregnancy plans, thyroid history, digestive symptoms, or upcoming procedures affect the decision?

A responsible prescriber should be able to discuss benefits, uncertainties, alternatives, and long-term planningnot merely provide a tracking number for the next shipment.

Real-World Experiences With GLP-1 Use Without Diabetes

The following observations reflect common patterns reported in clinical care and research rather than the experience of every patient.

The first surprise may be mental, not physical

Some users describe a noticeable reduction in “food noise,” meaning repetitive thoughts about snacks, portions, and the next meal. A person who previously felt hungry soon after breakfast may realize at lunchtime that the morning passed without constant negotiations with the pantry.

That change can feel freeing, but it also requires adjustment. People may have relied on food for comfort, celebration, boredom relief, or social connection. When appetite becomes quieter, emotions that were previously accompanied by eating may feel more visible.

Portion sizes can change quickly

A meal that once felt ordinary may suddenly feel enormous. Some people learn this lesson after eating their usual restaurant portion and spending the evening regretting their confidence. Slower eating becomes useful because fullness may arrive before the brain has finished admiring the fries.

Many patients do better with smaller meals, moderate fat, and deliberate hydration. However, eating too little can lead to fatigue, poor nutrient intake, constipation, dizziness, and muscle loss. Appetite suppression is a treatment effect, not an instruction to survive on crackers and optimism.

Dose increases may be the bumpiest part

A patient may tolerate the starting dose well and assume every later dose will be equally uneventful. Then an increase brings nausea, reflux, or constipation. This is why clinicians commonly increase doses gradually and may delay escalation when symptoms are troublesome.

The highest possible dose is not automatically the best dose. The appropriate level balances effectiveness and tolerability. Racing up the dosing ladder does not earn bonus points.

Progress is rarely a straight line

Some users lose weight rapidly at first, while others see modest changes until reaching a later dose. Weight can remain unchanged for several weeks even when waist size, blood pressure, mobility, or eating behavior improves.

Plateaus are normal. They do not necessarily mean the medication has permanently stopped working. Bodies adapt, calorie needs change, and day-to-day weight fluctuates with fluid, sodium, digestion, hormones, and the mysterious decisions of the household scale.

Strength training becomes more important

People losing substantial weight may lose both fat and lean tissue. Patients who include resistance exercise and adequate protein often feel better prepared to preserve strength. For someone new to exercise, that might mean supervised training, resistance bands, chair exercises, or short sessions rather than an immediate attempt to become an action-movie stunt double.

Social situations may feel different

Friends or relatives may comment on weight changes, ask intrusive questions, or assume the medication did all the work. Meanwhile, the user may be managing side effects, insurance appeals, exercise, meal planning, and fears about losing coverage.

Some people choose to discuss treatment openly; others keep it private. Neither approach requires an apology. A prescription is personal health information, not a community referendum.

The insurance experience can be as dramatic as the medication

Coverage may require documentation, prior authorization, proof of medical eligibility, or repeated appeals. A patient doing well may suddenly face a formulary change or denial. That disruption can be emotionally and physically difficult, especially when hunger returns or weight begins to rise.

Planning ahead with the prescribing team can help. Useful questions include whether another approved product is covered, whether the manufacturer offers legitimate assistance, and what maintenance strategy is available if treatment must stop.

Success is broader than a target weight

For one person, success may mean losing 15% of body weight. For another, it may mean walking upstairs without stopping, using less blood pressure medication, sleeping better, fitting comfortably into an airplane seat, or feeling less pain during daily activities.

The most durable experience is usually not “I took a shot and everything became easy.” It is closer to “The medication made biological obstacles more manageable, and I used that opportunity to build a healthier, sustainable routine.”

Conclusion

More people without diabetes are using GLP-1-based drugs because obesity-specific medications such as Wegovy and Zepbound can produce meaningful weight loss and, for selected patients, improve serious health outcomes. Their rise also represents a broader change in medicine: obesity is increasingly treated as a chronic disease influenced by biology, not dismissed as a simple shortage of willpower.

Yet popularity should not erase caution. GLP-1 medications can cause side effects, require long-term planning, and remain financially inaccessible to many Americans. Safe treatment begins with an appropriate diagnosis, a legitimate prescription, gradual dosing, nutritional support, strength-preserving activity, and regular follow-up.

The right question is not whether everyone should take a GLP-1 drug. It is whether a particular patient has a medical reason to use one, understands the risks and alternatives, and can follow a realistic plan for maintaining the benefits.

SEO Metadata